Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Journey Medical CorpDERM · Entity 6273 | CFO | April 22, 2026 | April 24, 2026 |
| Teligent, Inc.TLGT · Entity 134764 | VP, Controller, PAO | September 23, 2021 | October 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Journey Medical Corp
Report date April 22, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 261,371 |
Reported balance
After 2026-04-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-22 · Grant · Acquired 28,907 · Balance 261,371 F1: On April 22, 2026, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on April 22, 2027, 9,636 shares on April 22, 2028 and 9,635 shares on April 22, 2029. F2: Includes restricted stock units, which vest over various time periods. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2036-04-22 | Direct | 41,860 |
Reported balance
After 2026-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-22 · Grant · Acquired 41,860 · Balance 41,860 F3: On April 22, 2026, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on April 22, 2027, 13,953 shares on April 22, 2028 and 13,954 shares on April 22, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 22, 2026, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on April 22, 2027, 9,636 shares on April 22, 2028 and 9,635 shares on April 22, 2029.
F2: Includes restricted stock units, which vest over various time periods.
F3: On April 22, 2026, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on April 22, 2027, 13,953 shares on April 22, 2028 and 13,954 shares on April 22, 2029.
Teligent, Inc.
Report date September 23, 2021 · Filed October 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-09-23 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. One fourth of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on June 30, 2022. F2: These securities were issued pursuant to the terms of the 2016 Executive Incentive Plan as part of Reporting Person's annual compensation. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. One fourth of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on June 30, 2022.
F2: These securities were issued pursuant to the terms of the 2016 Executive Incentive Plan as part of Reporting Person's annual compensation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2026 Filed Apr 24, 2026 21:28 UTC | Journey Medical Corp DERM · Entity 6273 | GrantStock Option (Right to Buy) · Derivative | 41,860 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001104659-26-048733 · tm2612721-2_4seq1.xml · derivative · entry 2 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,860 Underlying: Common Stock, $0.0001 par value · 41,860 shares Expires 2036-04-22 F3 · derivative.exercise_date: On April 22, 2026, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on April 22, 2027, 13,953 shares on April 22, 2028 and 13,954 shares on April 22, 2029. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 21:28 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 28,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-048733 · tm2612721-2_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,371 F1 · shares: On April 22, 2026, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on April 22, 2027, 9,636 shares on April 22, 2028 and 9,635 shares on April 22, 2029. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:06 UTC | Journey Medical Corp DERM · Entity 6273 | GrantStock Option (Right to Buy) · Derivative | 41,860 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001104659-25-061155 · tm2518547-2_4seq1.xml · derivative · entry 2 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,860 Underlying: Common Stock, $0.0001 par value · 41,860 shares Expires 2035-06-17 F3 · derivative.exercise_date: On June 17, 2025, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on January 1, 2026, 13,953 shares on January 1, 2027 and 13,954 shares on January 1, 2028. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:06 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 28,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061155 · tm2518547-2_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,464 F1 · shares: On June 17, 2025, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on January 1, 2026, 9,636 shares on January 1, 2027 and 9,635 shares on January 1, 2028. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 02, 2025 Filed May 5, 2025 21:34 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 2,409 | $6.84 | $16,477.56 |
DisclosureSEC source: 0001104659-25-044611 · tm2514029-2_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,557 F1 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 2,409 of the underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on May 2, 2025, was $6.73 to $7.05. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 21:01 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 1,365 | $5.19 | $7,084.35 |
DisclosureSEC source: 0001104659-25-016490 · tm257335-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,966 F1 · shares: In connection with the vesting of restricted stock units on February 20, 2025, a total of 1,365 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 21, 2025, was $5.19 to $5.20. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 20:18 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 9,324 | $5.47 | $51,002.28 |
DisclosureSEC source: 0001104659-24-084916 · tm2420691-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,331 F1 · shares: In connection with the vesting of restricted stock units on July 31, 2024, a total of 9,324 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on August 1, 2024, was $5.45 to $5.55. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 20:01 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 4,055 | $5.40 | $21,897.00 |
DisclosureSEC source: 0001104659-24-081883 · tm2420028-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,655 F1 · shares: In connection with the vesting of restricted stock units on July 21, 2024, a total of 4,055 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 23, 2024, was $5.40 to $5.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 01, 2024 Filed Apr 16, 2025 23:06 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035598 · tm2512519-1_4seq1.xml · nonDerivative · entry 2 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,966 F2 · shares: On May 1, 2024, the reporting person was granted 80,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 26,666 shares on May 1, 2025, 26,667 shares on May 1, 2026 and 26,667 shares on May 1, 2027. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:54 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 2,450 | $3.75 | $9,187.50 |
DisclosureSEC source: 0001104659-24-027147 · tm247166-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,710 F1 · shares: In connection with the vesting of restricted stock units on February 20, 2024, a total of 2,768 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 22, 2024, was $3.73 to $3.78. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| January 03, 2024 Filed Apr 16, 2025 23:06 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035598 · tm2512519-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,966 F1 · shares: On January 3, 2024, the reporting person was granted 80,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that vested or will vest in accordance with the following schedule: 26,666 shares on July 3, 2024, 26,667 shares on July 3, 2025 and 26,667 shares on July 3, 2026. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:05 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 4,072 | $1.76 | $7,166.72 |
DisclosureSEC source: 0001104659-23-083825 · tm2322027-2_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,160 F1 · shares: In connection with the vesting of restricted stock units on July 24, 2023, a total of 4,072 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 24, 2023, was $1.76 to $1.80. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 22:01 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 2,768 | $1.97 | $5,452.96 |
DisclosureSEC source: 0001104659-23-024810 · tm237632-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,232 F1 · shares: In connection with the vesting of shares on February 20, 2023, a total of 2,768 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 21, 2023, was $1.95 to $1.98. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.